Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases

Chun-Xiao Wang; Xue Xue

doi:doi:10.11648/j.am.20170603.12

| Peer-Reviewed

Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases

Chun-Xiao Wang, Xue Xue

Published in Advances in Materials (Volume 6, Issue 3)

Received: 13 August 2017 Published: 14 August 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Nervous system diseases, such as Alzheimer's disease, stroke, and Parkinson's disease, are spreading around the world. These diseases involve complicatedly pathological processes, and so far, there are no effective medicines for therapy. Another type of psychiatric disorder is induced by drugs. The synthetic drugs, represented by methamphetamine, are becoming widely abuse. At present, the cure of methamphetamine dependence is mainly symptomatic treatment, but the recurrence rate is very high. As the common brain impairments in neuropsychiatric disease, it is necessary to summary novel strategies effectively restored brain function. In recent years, carbon nanotubes have attracted the attention due to their unique properties in the field of translational medicine. Recently, new advances reported that carbon nanotubes as a nanomedicine to treat various neuropsychiatric disorders. The purpose of this review is to introduce the therapeutic approaches and mechanisms of carbon nanotubes on neuropsychiatric disorders.

Published in	Advances in Materials (Volume 6, Issue 3)
DOI	10.11648/j.am.20170603.12
Page(s)	24-30
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Carbon Nanotubes, Neuropsychiatric Diseases, Autophagy, Mitochondrial Dysfunction

References

[1]	Mattson M P. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. Journal of Neurovirology. United States, vol. 8, pp. 539-550, December 2002.
[2]	Giraldo J P, Landry M P, Kwak S Y, et al. A Ratiometric Sensor Using Single Chirality Near-Infrared Fluorescent Carbon Nanotubes: Application to In Vivo Monitoring. Small. United States, vol. 11, pp. 3973-3984, August 2015.
[3]	Margaret Cretzmeyer, M. S. W., Mary Vaughan Sarrazin, et al. Treatment of methamphetamine abuse: research findings and clinical directions. Journal of Substance Abuse Treatment. United States, vol. 24, pp. 267-277, April 2003.
[4]	Nopparat C, Porter J M, Govitrapong P. The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy. Journal of Pineal Research. Thailand, vol. 49, pp. 382-389, November 2010.
[5]	Chang L, Alicata D, Ernst T, et al. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. United States, vol. 102, pp. 16-32, April 2007.
[6]	McCann U D, Kuwabara H, Kumar A, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse. United States, vol. 62, pp. 91-100, Febuary 2008.
[7]	Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Archives of General Psychiatry. Japan, vol. 63, pp. 90-100, January 2006.
[8]	Sekine Y, Ouchi Y, Sugihara G, et al. Methamphetamine causes microglial activation in the brains of human abusers. Journal of Neuroscience the Official Journal of the Society for Neuroscience. Japan, vol. 28, pp. 5756-5761, May 2008.
[9]	Howells F M, Uhlmann A, Temmingh H, et al. ¹H-magnetic resonance spectroscopy (¹H-MRS) in methamphetamine dependence and methamphetamine induced psychosis. Schizophrenia Research. South Africa, vol. 153, pp. 122-128, March 2014.
[10]	Barr A M, Panenka W J, Macewan G W, et al. The need for speed: an update on methamphetamine addiction. Journal of Psychiatry & Neuroscience Jpn. Canada, vol. 31, pp. 301-313, September 2006.
[11]	Orr M E, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer’s disease. Alzheimer's Research & Therapy. United States, vol. 5, pp. 1-9, October 2013.
[12]	Cuervo A M, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. United States, vol. 305, pp. 1292-1295, August 2004.
[13]	Wallace D C. Mitochondrial Diseases in Man and Mouse. Science. United States, vol. 283, pp. 1482-1488, March 1999.
[14]	Bubber P, Haroutunian V, Fisch G, et al. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Annals of Neurology. United States, vol. 57, pp. 695–703, May 2005.
[15]	Racay P, Tatarkova Z, Chomova M, et al. Mitochondrial calcium transport and mitochondrial dysfunction after global brain ischemia in rat hippocampus. Neurochemical Research. Slovak Republic, vol. 34, pp. 1469-1478, August 2009.
[16]	Ichas F, Mazat J P. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochimica Et Biophysica Acta. France, vol. 1366, pp. 33-50, August 1998.
[17]	Wang Q, Tang X N, Yenari M A. The inflammatory response in stroke. Journal of Neuroimmunology. United States, vol. 184, pp. 53-68, March 2007.
[18]	Niizuma K, Yoshioka H, Chen H, et al. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochimica et biophysica acta. United States, vol. 1802, pp. 92-99, January 2010.
[19]	Park K I, Teng Y D, Snyder E Y. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nature Biotechnology. Korea, vol. 20, pp. 1111-1117, November 2002.
[20]	Keefer E W, Botterman B R, Romero M I, et al. Carbon nanotube coating improves neuronal recordings. Nature Nanotechnology. United States, vol. 3, pp. 434-439, July 2008.
[21]	Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, et al. Dopaminergic reward system: a short integrative review. International Archives of Medicine. Germany, vol. 3, pp. 24, October 2010.
[22]	Mendelson J E, Boxenbaum H, Harris D S, et al. The Bioavailability of Intranasal and Smoked Methamphetamine. Clinical Pharmacology & Therapeutics. United States, vol. 74, pp. 475-486, November 2003.
[23]	Newton T F, Fong T, Chiang N, et al. A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacol Biochem Behav. United States, vol. 82, pp. 704-711, December 2005.
[24]	Sulzer D, Sonders M S, Poulsen N W, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology. United States, vol. 75, pp. 406-433, April 2005.
[25]	Shepard J D, Chuang D T, Shaham Y, et al. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology. United States, vol. 185, pp. 505-513, May 2006.
[26]	Krasnova I N, Cadet J L. Methamphetamine toxicity and messengers of death. Brain Research Reviews. United States, vol. 60, pp. 379-407, May 2009.
[27]	Shin E J, Duong C X, Nguyen X K, et al. Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cδ. Behav Brain Res. South Korea, vol. 232, pp. 98-113, June 2012.
[28]	Lin M, Chandramani-Shivalingappa P, Jin H, et al. Methamphetamine-induced neurotoxicity linked to ubiquitin-proteasome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells. Neuroscience. United States, vol. 210, pp. 308-332, May 2012.
[29]	De Vito M J, Wagner G C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. United States, vol. 28, pp. 1145-1150, October 1989.
[30]	Chan P, Monte D A, Luo J, et al. Rapid ATP Loss Caused by Methamphetamine in the Mouse Striatum: Relationship Between Energy Impairment and Dopaminergic Neurotoxicity. Journal of Neurochemistry. United States, vol. 62, pp. 2484-2487, June 1994.
[31]	Burrows K B, Gudelsky G, Yamamoto B K. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3, 4-methylenedioxymethamphetamine administration. European Journal of Pharmacology. United States, vol. 398, pp. 11-18, June 2000.
[32]	Esselens C, Oorschot V, Baert V, et al. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. Journal of Cell Biology. Belgium, vol. 166, pp. 1041-1054, September 2004.
[33]	Xue X, Wang L R, Sato Y, et al. Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Letters. China. vol. 14, pp. 5110-5117, September 2014.
[34]	Balas M, Constanda S, Duma-Voiculet A. Fabrication and toxicity characterization of a hybrid material based on oxidized and aminated MWCNT loaded with carboplatin. Toxicol In Vitro. United States, vol. 37, pp. 189-200, December 2016.
[35]	Lee H J, Park J, Yoon O J, et al. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nature Nanotechnology. Korea, vol. 6, pp. 121-125, February 2011.
[36]	Saleh A, Srinivasula S M, Acharya S, et al. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. Journal of Biological Chemistry. United States, vol. 274, pp. 17941-17945, June 1999.
[37]	Wang J, Li M, Shi Z, et al. Direct electrochemistry of cytochrome c at a glassy carbon electrode modified with single-wall carbon nanotubes. Analytical Chemistry. China, vol. 74, pp. 1993-1997, May 2002.
[38]	Ma X, Zhang L H, Wang L R, et al. Single-walled carbon nanotubes alter cytochrome c electron transfer and modulate mitochondrial function. Acs Nano. China, vol. 6, pp. 10486-10496, December 2012.
[39]	Wang L R, Xue X, Hu X M, et al. Structure-dependent mitochondrial dysfunction and hypoxia induced with single-walled carbon nanotubes. Small. China, vol. 10, pp. 2859-69, July 2014.
[40]	Yang C, Denno M E, Pyakurel P, et al. Recent trends in carbon nanomaterial-based electrochemical sensors for biomolecules: A review. Analytica Chimica Acta. United States, vol. 887, pp. 17-37, August 2015.
[41]	Jacobs C B, Ivanov I N, Nguyen M D, et al. High temporal resolution measurements of dopamine with carbon nanotube yarn microelectrodes. Analytical Chemistry. United States, vol. 86, pp. 5721-5727, June 2014.
[42]	Figueiredofilho L C, Silva T A, Vicentini F C, et al. Simultaneous voltammetric determination of dopamine and epinephrine in human body fluid samples using a glassy carbon electrode modified with nickel oxide nanoparticles and carbon nanotubes within a dihexadecylphosphate film. Analyst. Brazil, vol. 139, pp. 2842-2849, June 2014.
[43]	Xue X, Yang J Y, He Y, et al. Aggregated Single-Walled Carbon Nanotubes Attenuate the Behavioural and Neurochemical Effects of Methamphetamine in Mice. Nat Nanotechnol. China, vol. 7, pp. 613-20, July 2016.

Cite This Article

Plain Text BibTeX RIS

APA Style

Chun-Xiao Wang, Xue Xue. (2017). Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases. Advances in Materials, 6(3), 24-30. https://doi.org/10.11648/j.am.20170603.12

Copy | Download

ACS Style

Chun-Xiao Wang; Xue Xue. Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases. Adv. Mater. 2017, 6(3), 24-30. doi: 10.11648/j.am.20170603.12

Copy | Download

AMA Style

Chun-Xiao Wang, Xue Xue. Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases. Adv Mater. 2017;6(3):24-30. doi: 10.11648/j.am.20170603.12

Copy | Download

@article{10.11648/j.am.20170603.12,
  author = {Chun-Xiao Wang and Xue Xue},
  title = {Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases},
  journal = {Advances in Materials},
  volume = {6},
  number = {3},
  pages = {24-30},
  doi = {10.11648/j.am.20170603.12},
  url = {https://doi.org/10.11648/j.am.20170603.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.am.20170603.12},
  abstract = {Nervous system diseases, such as Alzheimer's disease, stroke, and Parkinson's disease, are spreading around the world. These diseases involve complicatedly pathological processes, and so far, there are no effective medicines for therapy. Another type of psychiatric disorder is induced by drugs. The synthetic drugs, represented by methamphetamine, are becoming widely abuse. At present, the cure of methamphetamine dependence is mainly symptomatic treatment, but the recurrence rate is very high. As the common brain impairments in neuropsychiatric disease, it is necessary to summary novel strategies effectively restored brain function. In recent years, carbon nanotubes have attracted the attention due to their unique properties in the field of translational medicine. Recently, new advances reported that carbon nanotubes as a nanomedicine to treat various neuropsychiatric disorders. The purpose of this review is to introduce the therapeutic approaches and mechanisms of carbon nanotubes on neuropsychiatric disorders.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases
AU  - Chun-Xiao Wang
AU  - Xue Xue
Y1  - 2017/08/14
PY  - 2017
N1  - https://doi.org/10.11648/j.am.20170603.12
DO  - 10.11648/j.am.20170603.12
T2  - Advances in Materials
JF  - Advances in Materials
JO  - Advances in Materials
SP  - 24
EP  - 30
PB  - Science Publishing Group
SN  - 2327-252X
UR  - https://doi.org/10.11648/j.am.20170603.12
AB  - Nervous system diseases, such as Alzheimer's disease, stroke, and Parkinson's disease, are spreading around the world. These diseases involve complicatedly pathological processes, and so far, there are no effective medicines for therapy. Another type of psychiatric disorder is induced by drugs. The synthetic drugs, represented by methamphetamine, are becoming widely abuse. At present, the cure of methamphetamine dependence is mainly symptomatic treatment, but the recurrence rate is very high. As the common brain impairments in neuropsychiatric disease, it is necessary to summary novel strategies effectively restored brain function. In recent years, carbon nanotubes have attracted the attention due to their unique properties in the field of translational medicine. Recently, new advances reported that carbon nanotubes as a nanomedicine to treat various neuropsychiatric disorders. The purpose of this review is to introduce the therapeutic approaches and mechanisms of carbon nanotubes on neuropsychiatric disorders.
VL  - 6
IS  - 3
ER  -

Copy | Download

Author Information

Chun-Xiao Wang

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China
Xue Xue

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Chun-Xiao Wang, Xue Xue. (2017). Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases. Advances in Materials, 6(3), 24-30. https://doi.org/10.11648/j.am.20170603.12

Copy | Download

ACS Style

Chun-Xiao Wang; Xue Xue. Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases. Adv. Mater. 2017, 6(3), 24-30. doi: 10.11648/j.am.20170603.12

Copy | Download

AMA Style

Chun-Xiao Wang, Xue Xue. Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases. Adv Mater. 2017;6(3):24-30. doi: 10.11648/j.am.20170603.12

Copy | Download

@article{10.11648/j.am.20170603.12,
  author = {Chun-Xiao Wang and Xue Xue},
  title = {Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases},
  journal = {Advances in Materials},
  volume = {6},
  number = {3},
  pages = {24-30},
  doi = {10.11648/j.am.20170603.12},
  url = {https://doi.org/10.11648/j.am.20170603.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.am.20170603.12},
  abstract = {Nervous system diseases, such as Alzheimer's disease, stroke, and Parkinson's disease, are spreading around the world. These diseases involve complicatedly pathological processes, and so far, there are no effective medicines for therapy. Another type of psychiatric disorder is induced by drugs. The synthetic drugs, represented by methamphetamine, are becoming widely abuse. At present, the cure of methamphetamine dependence is mainly symptomatic treatment, but the recurrence rate is very high. As the common brain impairments in neuropsychiatric disease, it is necessary to summary novel strategies effectively restored brain function. In recent years, carbon nanotubes have attracted the attention due to their unique properties in the field of translational medicine. Recently, new advances reported that carbon nanotubes as a nanomedicine to treat various neuropsychiatric disorders. The purpose of this review is to introduce the therapeutic approaches and mechanisms of carbon nanotubes on neuropsychiatric disorders.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases
AU  - Chun-Xiao Wang
AU  - Xue Xue
Y1  - 2017/08/14
PY  - 2017
N1  - https://doi.org/10.11648/j.am.20170603.12
DO  - 10.11648/j.am.20170603.12
T2  - Advances in Materials
JF  - Advances in Materials
JO  - Advances in Materials
SP  - 24
EP  - 30
PB  - Science Publishing Group
SN  - 2327-252X
UR  - https://doi.org/10.11648/j.am.20170603.12
AB  - Nervous system diseases, such as Alzheimer's disease, stroke, and Parkinson's disease, are spreading around the world. These diseases involve complicatedly pathological processes, and so far, there are no effective medicines for therapy. Another type of psychiatric disorder is induced by drugs. The synthetic drugs, represented by methamphetamine, are becoming widely abuse. At present, the cure of methamphetamine dependence is mainly symptomatic treatment, but the recurrence rate is very high. As the common brain impairments in neuropsychiatric disease, it is necessary to summary novel strategies effectively restored brain function. In recent years, carbon nanotubes have attracted the attention due to their unique properties in the field of translational medicine. Recently, new advances reported that carbon nanotubes as a nanomedicine to treat various neuropsychiatric disorders. The purpose of this review is to introduce the therapeutic approaches and mechanisms of carbon nanotubes on neuropsychiatric disorders.
VL  - 6
IS  - 3
ER  -

Copy | Download